ArticleRheumatology and therapy2024

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.

Lars Erik Kristensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.